The value of pre-emptive therapy for cytomegalovirus after liver transplantation

Transplantation Proceedings

Volumn 44, Issue 5, 2012, Pages 1357-1361

  Muller V ^a   Perrakis, A ^a   Meyer, J ^a   Fortsch T ^a   Korn, K ^a   Croner, R S ^a   Yedibela, S ^a   Hohenberger, W ^a   Schellerer, V S ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REINFECTION; SURVIVAL RATE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; GERMANY; GRAFT REJECTION; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84861868117     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.11.067     Document Type: Article

References (28)

1. Limaye AP, Bakthavatsalam R, Kim HW, et al: Impact oc cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81:1645, 2006
2. Falagas ME, Arbo M, Ruthazer R, et al: Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 63:1595, 1997
3. Cope AV, Sabin C, Burroughts A, et al: Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 176:1484, 1997
4. Dummer JS: Cytomegalovirus infection after liver transplantation: clinical manifestations and strategies for prevention. Rev Infect Dis 12(suppl 7):S767, 1990
5. de Otero J, Gavalda J, Murio E, et al: Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 26:865, 1998
6. Slifkin M, Ruthazer R, Freeman R, et al: Impact of cytomegalovirus prophylaxis on rejection following othotopic liver transplantation. Liver Transpl 11:1597, 2005
7. Park JM, Lake KD, Arenas JD, et al: Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalvirus disease in adult liver transplant recipients. Liver Transpl 12:112, 2006
8. Kanj SS, Sharara AI, Clavien PA, et al: Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 22:537, 1996
9. Saliba F, Arulnaden JL, Gugenheim J, et al: CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 21:2260, 1989
10. Jain A, Orloff M, Kashyap R, et al: Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 37:3182, 2005
11. Razonable RR, Rivero A, Rodriguez A, et al: Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxisn with oral ganciclovir. J Infect Dis 184:1461, 2001
12. Shibolet O, Ilan Y, Kalish Y, et al: Late cytomegalovirus disease following liver transplantation. Transpl Int 16:861, 2003
13. Akalin E, Sehgal V, Ames S, et al: Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3:73, 2003
14. Strippoli GF, Hodson EM, Jones C, et al: Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 81:139, 2006
15. Hodson EM, Barclay PG, Craig JC, et al: Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD003774, 2005
16. Hodson EM, Jones CA, Webster AC, et al: Antiviral medicaitons to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365:2105, 2005
17. Falagas ME, Snydman DR, Griffith J, et al: Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 126:275, 1997
18. Singh N: Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipietns. Clin Infect Dis 32:742, 2001
19. Singh N, Wannstedt C, Keyes L, et al: Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 79:1428, 2005
20. Lautenschlager I, Halme L, Hockerstedt K, et al: Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 8:21, 2006
21. Gane E, Saliba F, Valdecasas GJ, et al: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350:1729, 1997
22. Tzakis AG: Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation. Transpl Infect Dis (Suppl 2):35, 2001
23. Kalil AC, Levitsky J, Lyden E, et al: Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143:870, 2005
24. Arthurs SK, Eid AJ, Pedersen RA, et al: Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 13:1703, 2007
25. Singh N, Wannstedt C, Keyes L, et al: Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79: 85, 2005
26. Hoppe L, Marroni CA, Bressane R, et al: Impact of cytomegalovirus infection on long-term survival after orthotopic liver transplantation. Transplant Proc 38:192, 2006
27. Seehofer D, Rayes N, Neumann UP, et al: Changing impact of cytomegalovirus in liver transplantation - a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis. Transpl Int 18:941, 2005
28. Schmidt J, Müller SA, Mehrabi A, et al: Orthotope Leber-transplantation Chirurg 79:112, 2008